For thousands living with spinal muscular atrophy who aged out of early approvals, the FDA’s greenlight of an intrathecal gene therapy redrew the treatment map and challenged long‑held limits. The authorization of Itvisma, an intrathecal formulation of onasemnogene abeparvovec for patients two
When a lifesaving transplant risks unleashing the very immune fire meant to cure leukemia, choices about how to steer immunity before donor cells arrive determine whether patients heal or face harm. That dilemma sits at the heart of allogeneic hematopoietic stem cell transplantation, where
Chronic HIV infection, even under suppressive antiretroviral therapy, can trap the immune system in a state of simmering alarm that never fully resolves and quietly erodes the fitness of the very T cells needed for durable control of the virus. That conundrum has intensified attention on the small
Diving into the world of virology, we’re thrilled to speak with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development. With a deep understanding of technology and innovation in the industry, Ivan has been at the forefront of groundbreaking discoveries.
Imagine a world where life-saving cancer treatments no longer require weeks of waiting for cell processing or come with a price tag in the hundreds of thousands of dollars, but instead can be administered in days at a fraction of the cost. This is the promise of in vivo CAR cell therapy, an
In a landscape where patients with relapsed or refractory T-cell lymphoma face a grim prognosis, often with a median survival of just six months under current treatments, a new ray of hope has emerged through innovative research. This aggressive cancer, marked by limited therapeutic options, has
